Kymera Therapeutics, Inc. Financial Ratios
KYMR / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-19.7%
Profit Margin
-794.0%
Net Income / Revenue
Asset Turnover
0.02
Revenue / Total Assets
Equity Multiplier
1.10
Total Assets / Equity
Composite: -19.7% (reported: -19.7%)
Profitability
Liquidity
Current Ratio
10.47
Quick Ratio
10.47
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.02
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026
Earnings Quality
Accrual Ratio
-5.8%
-2.8pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.